Natera published validation data showing its tissue‑free MRD methylation assay (Latitude) correlates with disease‑free survival in colorectal cancer, reporting high specificity and clinically meaningful hazard ratios for postsurgical ctDNA positivity. The company highlighted lead times to relapse and concordance with competitor assays in a prospectively collected cohort. Separately, Natera submitted a Signatera CDx PMA to the FDA for use in muscle‑invasive bladder cancer to guide adjuvant immunotherapy with atezolizumab. The PMA is supported by randomized, Phase III IMvigor011 results showing improved outcomes in Signatera‑positive patients. Together, the papers and regulatory filing underscore growing momentum for ctDNA‑based MRD testing to guide adjuvant therapy decisions and surveillance strategies across oncology indications.